Organisation paid for research Program year 2025 Source: CMS Open Payments

Nephrology Associates

Neither a doctor nor a teaching hospital

Research payments

$294,383

48 payments

Through program year 2025, Nephrology Associates is reported as receiving $294,383 in research payments, across 48 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$3,175	1
2024	Research	$68,808	4
2023	Research	$36,075	4
2022	Research	$126,455	11
2021	Research	$57,975	12
2020	Research	$1,048	4
2019	Research	$848	12

Breakdown

Who paid Research payments · program years 2019–2025

AstraZeneca Pharmaceuticals LP $126,631 6 payments
Merit Medical Systems Inc $94,326 8 payments
Vertex Pharmaceuticals Incorporated $29,595 1 payment
GlaxoSmithKline, LLC. $18,854 14 payments
AstraZeneca UK Limited $13,772 2 payments
E.R. Squibb & Sons, L.L.C. $7,700 1 payment
Boehringer Ingelheim Pharmaceuticals, Inc. $2,450 1 payment
EMD Serono, Inc. $1,055 15 payments

Studies the money was for Research payments · program years 2019–2025

NEUTRALIZE - Lokelma Metabolic Acidosis Study A double-blind randomized placebo-controlled parallel design multicenter phase IIIb study of Lokelmas effect on serum potassium and serum bicarbonate in patients with CKD hyperkalemia and metabolic acidosis of CKD $140,403 8 payments
The Merit Wrapsody AV Access Efficacy Study $94,326 8 payments
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease $29,595 1 payment
A Phase 3 Randomized, Open-Label (Sponsor-Blind), Active-Controlled, P $18,854 14 payments
A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis $7,700 1 payment
BI 685509 Dose finding/PoCC in Non-Diabetic CKD $2,450 1 payment
Ms700461-0035 $636 9 payments
Ms 700461-0035 $212 3 payments
A Phase II, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy $208 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.